Presentation is loading. Please wait.

Presentation is loading. Please wait.

W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated.

Published byWinfred Benson Modified over 8 years ago

Similar presentations

Presentation on theme: "W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated."— Presentation transcript:

1 W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated GZR/EBR 100/50 mg qd –SOF 400 mg qd : PEG-IFN  -2b: 1.5  g/kg every week, weight-based RBV (1000 or 1200 mg/day)  Objective –SVR 12 (HCV RNA < 15 IU/ml), with 2 sided 95% confidence interval, non-inferiority margin – 10%, superiority if lower margin greater than 0 –Treatment-emergent adverse events 18-65 years HCV genotype 1 or 4 HCV RNA > 10 000 IU/ml Naïve or pre-treated with PEG-IFN + RBV Compensated cirrhosis allowed No HBV or HIV co-infection SOF + PEG-IFN + RBV C-EDGE HEAD-TO-HEAD N = 129 GZR/EBR SVR 12 * Randomisation was stratified on genotype (1a vs non-1a) and cirrhosis (presence or absence) Sperl J. J Hepatology 2016, Aug 16 (Epub ahead of print)

2 GZR/EBR n = 129 SOF + PEG-IFN + RBV n = 126 Age, mean (years)47.648.2 Female, %57.450.8 White race, %99.2 Il28B CC, %20.220.6 Baseline HCV RNA, % > 800 000 IU/ml69.864.3 > 2 000 000 IU/ml44.238.9 Genotype : 1a / 1b / 4, %14.0 / 81.4 / 4.713.5 / 82.5 / 4.0 Cirrhosis, %17.116.7 HCV treatment naïve77.572.2 PEG-IFN + RBV null response8.511.1 PEG-IFN + RBV partial response4.76.3 PEG-IFN + RBV relapse9.310.3 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Baseline characteristics C-EDGE HEAD-TO-HEAD Sperl J. J Hepatology 2016, Aug 16 (Epub ahead of print)

3 SVR 12 rates overall and by genotype Virologic failure Lost to follow-up/ discontinuation 0101 11 1 0000 0000 0101 9191 0000 2020 Genotype 4 0 20 40 60 80 100 129 99.2 All genotypesGenotype 1a % * Estimated adjusted difference : 8.8 % (95% CI : 3.6% ; 15.3%) 90.5 100 99 90.4 100 60 126651051041817 Genotype 1b GZR/EBRSOF + PEG-IFN + RBV  GZR/EBR is non-inferior and superior C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection C-EDGE HEAD-TO-HEAD Sperl J. J Hepatology 2016, Aug 16 (Epub ahead of print)

4 Resistance associated variants : prevalence in GZR/EBR group Detectable RAVs at baseline NS3 RAVs Genotype 1a10/18 (56%) : V36M (n=1), V55A (n=1), Q80K (n=2), V107I (n=1), S122G (n=3), I170V (n=2) Genotype 1b11/103 (11%) : V36L (n=1), V36I (n=1), T54S (n=5), V55A (n=1), V55I (n=2), Q80K (n=1), S122G (n=2), M175L (n=1) Genotype 4a0/1 Genotype 4d1/5 (20%) : V107I (n=1) NS5A RAVs Genotype 1a2/18 (11%) : M28V (n=2) Genotype 1b12/102 (12%) : Q30K (n=2), L31M (n=3), Y93H (n=7) Genotype 4a0/1 Genotype 4d1/5 (20%) : P58T (n=1) 100% of patients achieved SVR 12 with GZR/EBR, irrespective of presence or absence of baseline NS3 or NS5A RAVs C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Sperl J. J Hepatology 2016, Aug 16 (Epub ahead of print)

5 GZR/EBR N = 129 SOF + PEG-IFN + RBV N = 126 p Any treatment-emergent adverse event, %51.992.9< 0.001 Any treatment-related adverse event, %24.890.5< 0.001 Serious adverse event, %0.84ns Serious drug related adverse event, %02.40.078 Discontinuation due to drug-related adverse event, %00.8ns Neutrophil count < 0.75 x 10 9 /l, % 0 12.7< 0.001 Hemoglobin < 10 g/dl, %0.814.3< 0.001 Severe depression causing discontinuation, %00- Hepatic event causing discontinuation, %00- Treatment-emergent adverse events C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection C-EDGE HEAD-TO-HEAD Sperl J. J Hepatology 2016, Aug 16 (Epub ahead of print)

6  Summary –12 weeks of GZR/EBR has superior efficacy to SOF + PEG-IFN + RBV on genotype 1 and genotype 4-infected patients High SVR 12 in all subpopulations –Experienced patients including PEG-IFN + RBV null responders (100%) –Cirrhosis (100%) –High baseline viral load (98.9%) –Superior safety profile of GZR/EBR No serious drug-related adverse events No discontinuations due to drug-related adverse events Superior hematological safety profile No hepatic safety events C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection C-EDGE HEAD-TO-HEAD Sperl J. J Hepatology 2016, Aug 16 (Epub ahead of print)

Download ppt "W12 N = 126 C-EDGE HEAD-TO-HEAD Study: GZR/EBR vs SOF + PEF-IFN + RBV in genotype 1 or 4 infection Randomisation * 1:1  Design  Treatment regimens –Co-formulated."

Similar presentations

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.

Roth D. EASL 2015, Abs. LP02 C-SURFER Study: grazoprevir + elbasvir in genotype 1 with chronic kidney disease N = 111 GZR + EBR Placebo GZR + EBR (Intensive.
LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.

LDV/SOF 90/400 mg qd Non-randomised Open-label N = 21 W12 SVR 12 NIAID SYNERGY GT4 Kohli A. Lancet Infect Dis 2015; Juky 15, ePub ahead of print ≥ 18 years.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind 18-70 years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label 18-70 years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
OBV/PTV/r Open label 18-70 years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*
FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =

FISSION  Design  Objective –Non inferiority of SOF + RBV : SVR 12 (2-sided significance level of 5%, lower margin of the 95% CI for the difference =
AI444040 Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI444040 Study: DCV + SOF + RBV for genotypes 1, 2 and.

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.
No HBV or HIV co-infection

No HBV or HIV co-infection
SMV 150 + SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.

SMV SOF 400 Open-label OPTIMIST-2 Study: SMV + SOF for genotype 1 and cirrhosis W12  Objective –Superiority of SVR 12 (HCV RNA historical control.
SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : 1 18-70 years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥ 10.000.

SMV 150 mg QD + SOF 400 mg QD Randomisation 1 : years HCV genotype 1 Naïve or pre-treated with IFN-based regimen No cirrhosis HCV RNA ≥
UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.

UNITY-1 DCV/ASV/BCB No randomisation Open-label UNITY-1 Study: daclatasvir/asunaprevir/beclabuvir in genotype 1 without cirrhosis  Design W12 ≥ 18 years.
Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.

Reddy KR. Lancet Infect Dis. 2015;15:27-35 ATTAIN SMV + TVR placebo + PEG-IFN + RBV TVR + SMV placebo + PEG-IFN + RBV Randomisation* 1 : 1 Double-blind.
Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64:948-56 COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.

Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.
ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml.

ION-4  Design LDV/SOF Open-label ION-4 Study: LDV/SOF in HIV co-infection W12 ≥ 18 years Chronic HCV infection Genotype 1 or 4 HCV RNA ≥ 10,000 IU/ml.
ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.

ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.
ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.

ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.
OBV/PTV/r Placebo Randomisation** 2 : 1 18-75 years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.

OBV/PTV/r Placebo Randomisation** 2 : years Chronic HCV Genotype 1b HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated, no prior failure with DAA Without.
TURQUOISE-I OBV/PTV/r + DSV + RBV Randomisation* 1 : 1 Open-label 18-70 years HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated with PEG-IFN +

TURQUOISE-I OBV/PTV/r + DSV + RBV Randomisation* 1 : 1 Open-label years HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Naïve or pre-treated with PEG-IFN +
No randomization N = 59 W12W24 Arm B : compensated cirrhosis N = 31 N = 29 Arm C : compensated cirrhosis Arm A : No cirrhosis AGATE-II Study: OBV/PTV/r.

No randomization N = 59 W12W24 Arm B : compensated cirrhosis N = 31 N = 29 Arm C : compensated cirrhosis Arm A : No cirrhosis AGATE-II Study: OBV/PTV/r.
ALLY-3  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI DCV 60 mg qd + SOF 400 mg qd Not randomised Open-label ALLY-3 Study: DCV + SOF for.

ALLY-3  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI DCV 60 mg qd + SOF 400 mg qd Not randomised Open-label ALLY-3 Study: DCV + SOF for.

Similar presentations

Ads by Google